HRP20220683T1 - Liječenje parkinsonove bolesti - Google Patents

Liječenje parkinsonove bolesti Download PDF

Info

Publication number
HRP20220683T1
HRP20220683T1 HRP20220683TT HRP20220683T HRP20220683T1 HR P20220683 T1 HRP20220683 T1 HR P20220683T1 HR P20220683T T HRP20220683T T HR P20220683TT HR P20220683 T HRP20220683 T HR P20220683T HR P20220683 T1 HRP20220683 T1 HR P20220683T1
Authority
HR
Croatia
Prior art keywords
compound
parkinson
disease
treatment
methylbenzoyl
Prior art date
Application number
HRP20220683TT
Other languages
English (en)
Croatian (hr)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji MANDHANE
Manoj Atmaramji UPADHYA
Sameer Vishwanath MEHETRE
Gajanan Uttamrao CHIDREWAR
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of HRP20220683T1 publication Critical patent/HRP20220683T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20220683TT 2016-06-02 2017-06-02 Liječenje parkinsonove bolesti HRP20220683T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
HRP20220683T1 true HRP20220683T1 (hr) 2022-07-08

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220683TT HRP20220683T1 (hr) 2016-06-02 2017-06-02 Liječenje parkinsonove bolesti

Country Status (26)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
EP3982964A1 (en) * 2019-06-11 2022-04-20 Sun Pharma Advanced Research Company Ltd Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665709B1 (en) * 2011-01-21 2016-12-07 Sun Pharma Advanced Research Company Limited Diarylacetylene hydrazide containing tyrosine kinase inhibitors
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
CA2985161A1 (en) * 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas

Also Published As

Publication number Publication date
PH12018502457B1 (en) 2022-01-12
US20190275017A1 (en) 2019-09-12
KR102508288B1 (ko) 2023-03-09
MY193754A (en) 2022-10-27
US20210015805A1 (en) 2021-01-21
LT3463351T (lt) 2022-06-10
EP3463351B1 (en) 2022-04-27
US20220273632A1 (en) 2022-09-01
SG11201810294QA (en) 2018-12-28
CL2018003431A1 (es) 2019-05-10
UA123018C2 (uk) 2021-02-03
US11813252B2 (en) 2023-11-14
PL3463351T3 (pl) 2022-06-20
DK3463351T3 (da) 2022-06-07
IL263188B (en) 2021-08-31
RS63243B1 (sr) 2022-06-30
CA3024976A1 (en) 2017-12-07
CN109475539A (zh) 2019-03-15
SMT202200228T1 (it) 2022-07-21
US20240066014A1 (en) 2024-02-29
IL263188A (en) 2018-12-31
MX2018014944A (es) 2019-03-07
MX385276B (es) 2025-03-18
CN109475539B (zh) 2021-12-28
KR20190015257A (ko) 2019-02-13
US10849887B2 (en) 2020-12-01
AU2017273415A1 (en) 2018-12-06
CY1125285T1 (el) 2025-03-28
BR112018074439A2 (pt) 2019-03-06
PH12018502457A1 (en) 2019-10-21
JP6974357B2 (ja) 2021-12-01
HUE059387T2 (hu) 2022-11-28
US11583522B2 (en) 2023-02-21
ES2914782T3 (es) 2022-06-16
SI3463351T1 (sl) 2022-07-29
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
NZ748592A (en) 2025-11-28
EP3463351A1 (en) 2019-04-10
PT3463351T (pt) 2022-06-02
WO2017208267A1 (en) 2017-12-07
EP4085912A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
MY176210A (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20230274T1 (hr) Kemijski spojevi
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
ME02910B (me) Spojevi tetrahidropirolotiazina
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
AR103680A1 (es) Inhibidores selectivos de bace1
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
JP2016510326A5 (enExample)
HRP20221098T1 (hr) Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5
FI3206692T3 (fi) Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja
HRP20191744T1 (hr) 1-[2-(aminometil)benzil]-2-tiokso-1,2,3,5-tetrahidro-4h-pirolo[3,2-d]pirimidin-4-oni kao inhibitori mijeloperoksidaze
ME02405B (me) Spojevi pirazola као inhibitori sglt1
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA201792170A1 (ru) Производные индола